Express News | Baoyang Pharmaceutical Group signed an agreement with Peking University Hospital.

BreakingsDec 12 21:37

Baiyang Pharma (301015.SZ): plans to increase capital by 24.2904 million yuan to Zhongshan Anshi.

On December 10, Gelonghui reported that Baiyang Pharmaceuticals (301015.SZ) announced that according to business development needs, its subsidiary, Ansai Pharmaceutical (Zhongshan) Co., Ltd. (hereinafter referred to as "Zhongshan Ansai"), intends to increase its registered capital from 26.65738 million yuan to 100 million yuan, with an additional registered capital of 73.34262 million yuan, which will be proportionally increased by all shareholders according to their shareholding ratios. The company and its wholly-owned subsidiary, Baiyang Group Limited (hereinafter referred to as "Baiyang Limited"), intend to increase their investment in Zhongshan Ansai by 2.42 according to their shareholding ratio.

Gelonghui FinanceDec 10 16:45

Baiyang Medical (301015.SZ): Currently has established a presence in the high-end medical instruments sector with products such as atricure's atrial fibrillation treatment equipment and Tongxin Medical's full magnetic suspension artificial heart.

Gelonghui November 28th | Baiyang Pharmaceutical (301015.SZ) stated in recent investor relations activities that the company has already laid out Atricure's atrial fibrillation treatment equipment, Tongxin Medical's full magnetic levitation artificial heart, Maidis' ultrasound electromagnetic positioning puncture guidance device, and Wudiankang's home ECG monitor and other products in the high-end medical instruments field; Recently, the company has obtained the exclusive commercial operation rights of ZAP Surgical's ZAP-X Mars boat radiosurgery robot in mainland China and Hong Kong and Macau regions.

Gelonghui FinanceNov 28 17:29

Secured a 10-year market promotion rights for Huahao Zhongtian's innovative drugs for breast cancer, Baiyang Pharmaceutical increases investment in the oncology field.

Baiyang Pharmaceuticals stated that the company has obtained the exclusive promotion rights for Youtidi in all medical institutions and pharmaceutical retail enterprises in mainland china, expanding the company's brand matrix in serious pharmaceutical categories such as oncology. If the agreement is implemented smoothly, it will help enhance the company's sustained profitability and have a positive impact on its performance.

lanjinger.comNov 15 18:46

Huahao Zhongtian Pharmaceuticals-B (02563.HK) signed a market promotion service agreement with Baiyang Yiyao's Baiyang Zhihe.

November 14th, HealthPulse: Huahao Zhongtian Pharmaceuticals-B (02563.HK) announced that it has recently signed a market promotion service agreement with Baiyang Pharmaceuticals' wholly-owned subsidiary, Beijing Baiyang Zhihe Medical Scientific Results Transformation Service Co., Ltd. ("Baiyang Zhihe"). According to the market promotion service agreement, the company agrees to grant Baiyang Zhihe the exclusive market promotion service for YoutideLong Injection (trade name: Youtidi) in all medical institutions and pharmaceutical retail enterprises in mainland China. In addition, the company, its wholly-owned subsidiary Chengdu Huahao Zhongtian, and Baiyang Zhihe have signed a supplementary agreement to the market promotion service agreement. According to the supplementary agreement,

Gelonghui FinanceNov 14 16:51

Baiyang Pharmaceuticals (301015): Core business maintains steady growth, successful acquisition of pharmaceutical industry.

The company released its third quarter report for 2024, achieving revenue of 6.144 billion yuan in the first three quarters of 2024, a year-on-year increase of 2.65%; achieving a net income attributable to shareholders of the listed company of 0.641 billion yuan.

Changjiang SecuritiesNov 11 08:17